FENNEC PHARMACEUTICALS INC. 8-K

What Happened
Fennec Pharmaceuticals, Inc. (FENC) filed a Form 8-K on April 22, 2026 to report that four abstracts evaluating PEDMARK® (sodium thiosulfate injection) were accepted for presentation or publication at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The company furnished a press release dated April 21, 2026 as Exhibit 99.1 to the filing.

Key Details

• Four abstracts evaluating PEDMARK were accepted for presentation or publication at ASCO 2026.
• Product named: PEDMARK® (sodium thiosulfate injection).
• Press release announcing the acceptances dated April 21, 2026; Form 8-K filed April 22, 2026.
• ASCO 2026 location: Chicago, Illinois.

Why It Matters
Acceptance of multiple abstracts at a major oncology meeting increases scientific visibility for PEDMARK and communicates clinical and developmental progress to physicians, researchers, and investors. This 8-K is informational: it documents upcoming data dissemination but does not report financial results or changes in management. Investors tracking Fennec’s clinical program and commercial prospects for PEDMARK should note the planned ASCO presentations as potential catalysts for increased attention or follow-up data releases.